Treating urogenital atrophy

Authors: Brown, Candace; Bachman, Gloria

Source: Women's Health, Volume 1, Number 2, September 2005 , pp. 279-292(14)

Publisher: Future Medicine

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

Urogenital atrophy, although a frequently occurring symptom of aging for all women, is a condition often not thought of as a symptom of distress for older women or a sign of pelvic pathology requiring treatment by clinicians. Rather, many clinicians feel it is an expected consequence of aging, and older women themselves assimilate their lifestyle to the uncomfortable symptoms of dryness, irritation, itching and malodorous discharge. At times, when symptoms become intolerable with coitus, women will abandon sexual intercourse with their partners due to dyspareunia and not seek intervention to reverse the condition owing to embarrassment in raising this sensitive topic. When urogenital atrophy is diagnosed and the patient requests treatment, the gold standard intervention is estrogen, which can either be delivered systemically or vaginally. Since the Women’s Health Initiative data, low-dose, vaginally delivered estrogen is recommended.

Keywords: atrophic vaginitis; dyspareunia; hypoestrogenic tissue; nonhormonal lubricants; urogenital atrophy; vaginal estrogen

Document Type: Research article

DOI: http://dx.doi.org/10.2217/17455057.1.2.279

Affiliations: 1: 1University of Tennesse Health Science Center, Memphis, Tennessee, USA., Email: csbrown@utmem.edu

Publication date: 2005-09-01

More about this publication?
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page